Multilayered Polyurethane/Poly(vinyl alcohol) Nanofibrous Mats for Local Topotecan Delivery as a Potential Retinoblastoma Treatment.

cytotoxicity multilayered structure nanofibers needleless electrospinning prolonged release retinoblastoma topotecan

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
03 May 2023
Historique:
received: 15 03 2023
revised: 27 04 2023
accepted: 28 04 2023
medline: 27 5 2023
pubmed: 27 5 2023
entrez: 27 5 2023
Statut: epublish

Résumé

Local chemotherapy using polymer drug delivery systems has the potential to treat some cancers, including intraocular retinoblastoma, which is difficult to treat with systemically delivered drugs. Well-designed carriers can provide the required drug concentration at the target site over a prolonged time, reduce the overall drug dose needed, and suppress severe side effects. Herein, nanofibrous carriers of the anticancer agent topotecan (TPT) with a multilayered structure composed of a TPT-loaded inner layer of poly(vinyl alcohol) (PVA) and outer covering layers of polyurethane (PUR) are proposed. Scanning electron microscopy showed homogeneous incorporation of TPT into the PVA nanofibers. HPLC-FLD proved the good loading efficiency of TPT (≥85%) with a content of the pharmacologically active lactone TPT of more than 97%. In vitro release experiments demonstrated that the PUR cover layers effectively reduced the initial burst release of hydrophilic TPT. In a 3-round experiment with human retinoblastoma cells (Y-79), TPT showed prolonged release from the sandwich-structured nanofibers compared with that from a PVA monolayer, with significantly enhanced cytotoxic effects as a result of an increase in the PUR layer thickness. The presented PUR-PVA/TPT-PUR nanofibers appear to be promising carriers of active TPT lactone that could be useful for local cancer therapy.

Identifiants

pubmed: 37242640
pii: pharmaceutics15051398
doi: 10.3390/pharmaceutics15051398
pmc: PMC10222511
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Biomed Res Int. 2021 Jul 03;2021:9968602
pubmed: 34285920
J Pharm Sci. 1992 Jul;81(7):676-84
pubmed: 1403703
Pharmaceutics. 2019 Apr 03;11(4):
pubmed: 30987206
Front Oncol. 2022 Apr 01;12:822330
pubmed: 35433448
Int J Pharm. 2021 Sep 5;606:120871
pubmed: 34246742
J Chromatogr B Biomed Appl. 1995 Jun 9;668(1):107-15
pubmed: 7550966
Beilstein J Nanotechnol. 2015 Sep 25;6:1939-45
pubmed: 26665065
Colloids Surf B Biointerfaces. 2016 Oct 1;146:624-31
pubmed: 27429296
Adv Mater. 2018 Aug;30(31):e1706665
pubmed: 29756237
Eur J Pharm Biopharm. 2012 May;81(1):1-13
pubmed: 22342778
Mater Sci Eng C Mater Biol Appl. 2019 Oct;103:109799
pubmed: 31349439
Int J Pharm. 2019 Mar 10;558:268-283
pubmed: 30611748
Tissue Eng Part A. 2022 Dec;28(23-24):958-967
pubmed: 36181351
J Control Release. 2005 Jun 20;105(1-2):43-51
pubmed: 15908033
Int J Pharm. 2017 May 15;523(1):151-158
pubmed: 28341150
Clin Pharmacokinet. 1996 Aug;31(2):85-102
pubmed: 8853931
Molecules. 2019 Feb 26;24(5):
pubmed: 30813599
Macromol Biosci. 2018 Jun;18(6):e1800011
pubmed: 29688614
Pharm Res. 2017 Jul;34(7):1391-1401
pubmed: 28405914
Clin Cancer Res. 2005 Oct 15;11(20):7569-78
pubmed: 16243833
Ann N Y Acad Sci. 2000;922:36-45
pubmed: 11193923
J Control Release. 2016 Aug 10;235:125-133
pubmed: 27221069
Small. 2018 Jun 27;:e1801183
pubmed: 29952070
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Jun;163(2):122-131
pubmed: 30967685
Eur J Pharm Biopharm. 2011 Sep;79(1):189-96
pubmed: 21352915
J Control Release. 2010 Jan 4;141(1):13-21
pubmed: 19686789
PLoS One. 2016 Jul 28;11(7):e0160094
pubmed: 27467588
Onco Targets Ther. 2019 Jul 30;12:6069-6082
pubmed: 31534347
Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2126-34
pubmed: 19834044
Mater Sci Eng C Mater Biol Appl. 2017 Jul 1;76:782-786
pubmed: 28482590
Int J Nanomedicine. 2012;7:5315-25
pubmed: 23071393
Int J Mol Sci. 2019 Mar 02;20(5):
pubmed: 30832308
J Control Release. 2014 Jul 10;185:12-21
pubmed: 24768792
J Control Release. 2015 Sep 28;214:23-9
pubmed: 26160309
J Control Release. 2006 May 30;112(3):333-42
pubmed: 16650910
Nanomedicine. 2015 Jul;11(5):1047-56
pubmed: 25804412
J Pharm Biomed Anal. 1990;8(8-12):681-3
pubmed: 2100606
Drug Deliv Transl Res. 2012 Dec;2(6):477-88
pubmed: 25787326
Food Chem. 2020 Mar 5;308:125599
pubmed: 31648098
Mater Sci Eng C Mater Biol Appl. 2019 May;98:982-993
pubmed: 30813105
J Control Release. 2011 Nov 30;156(1):21-7
pubmed: 21777632
Int J Pharm. 2021 Sep 5;606:120832
pubmed: 34175379
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022 May;14(3):e1772
pubmed: 34964277
Pharmaceutics. 2022 Apr 20;14(5):
pubmed: 35631489
Retina. 2014 Sep;34(9):1719-27
pubmed: 25099219

Auteurs

Radka Hobzova (R)

Institute of Macromolecular Chemistry, Czech Academy of Sciences, 162 06 Prague, Czech Republic.

Jakub Sirc (J)

Institute of Macromolecular Chemistry, Czech Academy of Sciences, 162 06 Prague, Czech Republic.

Kusum Shrestha (K)

Institute of Macromolecular Chemistry, Czech Academy of Sciences, 162 06 Prague, Czech Republic.

Barbora Mudrova (B)

Department of Analytical Chemistry, Faculty of Science, Charles University, 128 43 Prague, Czech Republic.

Zuzana Bosakova (Z)

Department of Analytical Chemistry, Faculty of Science, Charles University, 128 43 Prague, Czech Republic.

Miroslav Slouf (M)

Institute of Macromolecular Chemistry, Czech Academy of Sciences, 162 06 Prague, Czech Republic.

Marcela Munzarova (M)

Nanomedical Co., Ltd., 463 12 Liberec, Czech Republic.

Jan Hrabeta (J)

Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, 150 06 Prague, Czech Republic.

Tereza Feglarova (T)

Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, 150 06 Prague, Czech Republic.

Ana-Irina Cocarta (AI)

Institute of Macromolecular Chemistry, Czech Academy of Sciences, 162 06 Prague, Czech Republic.

Classifications MeSH